Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of SIG-001 in Adult Patients With Severe or Moderately-Severe Haemophilia A Without Inhibitors (SIG-001-121)

Next Previous
Search
Trial Profile

A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of SIG-001 in Adult Patients With Severe or Moderately-Severe Haemophilia A Without Inhibitors (SIG-001-121)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SIG 001 (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; First in man
  • Sponsors Sigilon Therapeutics

    • Most Recent Events

    • 07 Nov 2022 Status changed from suspended to discontinued.
    • 29 Nov 2021 According to a Sigilon Therapeutics media release, the company today reported that fibrosed spheres were observed during a retrieval procedure in a patient in this study. All three patients enrolled in the SIG-001 trial will continue to be followed per study protocol.
    • 10 Nov 2021 According to a Sigilon Therapeutics media release, the company expects o provide up to 12 months of follow-up data for three patients from the safety and dose-ranging study of SIG-001 in severe to moderate-severe hemophilia A in the fourth quarter of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top